Zacks Investment Research Lowers Grifols SA (GRFS) to Hold
According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “
Shares of Grifols SA (NASDAQ:GRFS) opened at 15.85 on Wednesday. The company has a 50-day moving average price of $16.08 and a 200 day moving average price of $16.06. Grifols SA has a one year low of $14.07 and a one year high of $18.04. The company has a market capitalization of $21.66 billion, a price-to-earnings ratio of 35.94 and a beta of 0.92.
Several institutional investors have recently bought and sold shares of the company. Pacad Investment Ltd. bought a new position in Grifols SA during the first quarter worth $196,000. Ngam Advisors L.P. increased its position in Grifols SA by 92.0% in the first quarter. Ngam Advisors L.P. now owns 80,859 shares of the company’s stock worth $1,251,000 after buying an additional 38,748 shares during the period. BlackRock Fund Advisors increased its position in Grifols SA by 122.4% in the first quarter. BlackRock Fund Advisors now owns 1,971,950 shares of the company’s stock worth $30,506,000 after buying an additional 1,085,139 shares during the period. JPMorgan Chase & Co. increased its position in Grifols SA by 158.5% in the first quarter. JPMorgan Chase & Co. now owns 2,447,784 shares of the company’s stock worth $37,867,000 after buying an additional 1,501,036 shares during the period. Finally, Credit Agricole S A increased its position in Grifols SA by 27.0% in the first quarter. Credit Agricole S A now owns 455,800 shares of the company’s stock worth $7,051,000 after buying an additional 96,900 shares during the period. 20.18% of the stock is currently owned by institutional investors and hedge funds.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Grifols SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA and related companies with MarketBeat.com's FREE daily email newsletter.